Publication: Should One Use the Combination of Abiraterone and Poly(ADP-Ribose) Polymerase Inhibitors as First-Line Therapy for All Patients With Metastatic Castration-Resistant Prostate Cancer
| dc.authorscopusid | 36613077200 | |
| dc.authorscopusid | 57219376656 | |
| dc.authorscopusid | 55349813400 | |
| dc.authorwosid | Gumusay, Ozge/Aat-3435-2021 | |
| dc.contributor.author | Cetin, Bulent | |
| dc.contributor.author | Wabl, Chiara A. | |
| dc.contributor.author | Gumusay, Ozge | |
| dc.contributor.authorID | Gumusay, Ozge/0000-0002-6236-9829 | |
| dc.date.accessioned | 2025-12-11T01:02:35Z | |
| dc.date.issued | 2022 | |
| dc.department | Ondokuz Mayıs Üniversitesi | en_US |
| dc.department-temp | [Cetin, Bulent] Ondokuz Mayis Univ, Div Med Oncol, Fac Med, 1Department Internal Med, TR-55280 Samsun, Turkey; [Wabl, Chiara A.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; [Gumusay, Ozge] Acibadem Univ, Sch Med, Dept Internal Med, Div Med Oncol, TR-34752 Istanbul, Turkey | en_US |
| dc.description | Gumusay, Ozge/0000-0002-6236-9829; | en_US |
| dc.description.woscitationindex | Science Citation Index Expanded | |
| dc.identifier.doi | 10.2217/fon-2022-0668 | |
| dc.identifier.endpage | 4238 | en_US |
| dc.identifier.issn | 1479-6694 | |
| dc.identifier.issn | 1744-8301 | |
| dc.identifier.issue | 39 | en_US |
| dc.identifier.pmid | 36651304 | |
| dc.identifier.scopus | 2-s2.0-85150751726 | |
| dc.identifier.scopusquality | Q3 | |
| dc.identifier.startpage | 4235 | en_US |
| dc.identifier.uri | https://doi.org/10.2217/fon-2022-0668 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/40889 | |
| dc.identifier.volume | 18 | en_US |
| dc.identifier.wos | WOS:000918715700001 | |
| dc.identifier.wosquality | Q3 | |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis Ltd | en_US |
| dc.relation.ispartof | Future Oncology | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Advanced Prostate Cancer | en_US |
| dc.subject | Homologous Recombination Repair | en_US |
| dc.subject | PARP Inhibitors | en_US |
| dc.title | Should One Use the Combination of Abiraterone and Poly(ADP-Ribose) Polymerase Inhibitors as First-Line Therapy for All Patients With Metastatic Castration-Resistant Prostate Cancer | en_US |
| dc.type | Editorial | en_US |
| dspace.entity.type | Publication |
